Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Versamatrix was a Danish biotechnology company specializing in the development and manufacturing of advanced resin technologies for solid-phase peptide synthesis (SPPS) and combinatorial chemistry. Founded by Nobel laureate Morten Meldal, the company's proprietary VersaMatrix platform provided high-performance polymer supports designed to improve the efficiency and purity of complex molecule production. The company served the pharmaceutical and biotech industries by providing specialized tools for drug discovery and development. In 2011, Versamatrix was acquired by Biotage, a global life sciences tools company, to enhance its portfolio in peptide synthesis and purification. The acquisition allowed Biotage to integrate Versamatrix's unique resin technology into its existing automated synthesis systems.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on VersaMatrix.